Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Uses of icariin or icariside II in prevention and treatment of kidney diseases

A technology of icariin and icariin is applied in the fields of urinary system diseases, medical preparations containing active ingredients, organic active ingredients, etc., and can solve the problem of unable to block the pathological changes of chronic kidney disease.

Active Publication Date: 2015-11-25
北京东方百奥医药开发有限公司
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these treatment options can slow down the development of kidney disease to a certain extent, they still cannot block the pathological changes of chronic kidney disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of icariin or icariside II in prevention and treatment of kidney diseases
  • Uses of icariin or icariside II in prevention and treatment of kidney diseases
  • Uses of icariin or icariside II in prevention and treatment of kidney diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] The preparation of embodiment 1 icariin and icariin II

[0051] Icariin and Epimedium were prepared according to the method of XiaQ et al. Inosin II.

[0052] Preparation of icariin: extraction with ethanol and purification with macroporous resin to extract and separate icariin from Epimedium. A large amount of icariin (Icariin, ICA) can be obtained. Its purity was 98.0% by HPLC analysis.

[0053] Preparation of Icariside II:

[0054] In vitro, the icariin in Epimedium was converted into icariside Ⅱ (Icariside Ⅱ, ICA Ⅱ) by glycosidase (β-glucosidase) fermentation, and purified according to the literature method. Utilize HPLC to analyze its purity to be 98.0% (as figure 1 ).

[0055] The prepared icariin and icariin II were used in the following examples.

Embodiment 2

[0056] Example 2 Prevention and treatment effect of icariside Ⅱ on chronic kidney disease caused by diabetes

[0057] 1. Establishment of renal endogenous stem cell marker chronic kidney disease rat model

[0058] Chronic kidney disease is mainly caused by diabetes, hypertensive renal arteriosclerosis, glomerulonephritis, and nephrotoxic drugs. Among them, the chronic kidney disease model in diabetic rats is one of the most commonly used and reasonable models.

[0059]The inventor used 50 SD rats and injected EdU (thymidine analog) (50 mg / kg) (Invitrogen, Carlsbad, CA, USA) intraperitoneally on the second day after birth to prepare experiments carrying EdU(+)-LRCs Rats), raised for 8 weeks, were randomly divided into healthy control group NC (n=10), and the remaining rats were fasted by intraperitoneal injection of STZ (60mg / kg, ip) (SigmaChemicalCo, StLouis, Missouri) to establish a diabetes model group (n =40), 72 hours after STZ injection, the blood glucose was detected t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to uses of icariin or icariside II, specifically to uses of icariin, icariside II or pharmaceutically acceptable salts thereof in preparation of products for prevention and treatment of kidney diseases, specifically chronic kidney diseases. According to the present invention, with the icariin and the icariside II, the kidney endogenous stem cells of the EdU label can be increased and recruited, the TGF[beta] / Smad, CTGF, P-ERK1 / 2 phosphorylation level can be regulated, the pathological changes of endothelial cells, glomerular basement membrane and kidney tubules can be improved, the proteinuria can be reduced, the urea nitrogen and creatinine clearance level can be improved, the pathological change progression of the chronic kidney disease can be delayed, and the risk of the renal dysfunction can be reduced, such that the icariin and the icariside II can be used for prevention or treatment of kidney diseases.

Description

technical field [0001] The present invention relates to the use of icariin and icariin II, in particular to the use of icariin and icariin II in preparing products for preventing and treating kidney diseases or improving kidney function. Background technique [0002] Epidemiological surveys show that the prevalence of chronic kidney disease among Chinese adults reaches 10.8%. Based on this, it is estimated that there are 120 million adult patients with chronic kidney disease. High-risk groups for chronic kidney disease mainly include patients with diabetes, hypertension, the elderly over 65 years old, those taking nephrotoxic drugs for a long time, and those with a family history of chronic kidney disease. [0003] The basic pathological changes of chronic kidney disease are characterized by glomerular mesangial cell proliferation and matrix increase, glomerular basement membrane thickening, and finally glomerular fibrosis leading to glomerulosclerosis. 84% of the patients ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P13/12
Inventor 辛钟成田贞姬辛华郭应禄郭素梅林倩玉
Owner 北京东方百奥医药开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com